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Abstract. The development of the skeleton requires 
the coordinated activities of bone-forming osteoblasts 
and bone-resorbing osteoclasts. The activities of these 
two cell types are likely to be regulated by TGF-[3, 
which is abundant in bone matrix. We have used trans- 
genic mice to evaluate the role of TGF-[32 in bone de- 
velopment and turnover. Osteoblast-specific overex- 
pression of TGF-132 from the osteocalcin promoter 
resulted in progressive bone loss associated with in- 
creases in osteoblastic matrix deposition and osteoclas- 
tic bone resorption. This phenotype closely resembles 
the bone abnormalities seen in human hyperparathy- 
roidism and osteoporosis. Furthermore, a high level of 
TGF-[32 overexpression resulted in defective bone min- 
eralization and severe hypoplasia of the clavicles, a 
hallmark of the developmental disease cleidocranial 
dysplasia. Our results suggest that TGF-[32 functions as 
a local positive regulator of bone remodeling and that 
alterations in TGF-132 synthesis by bone cells, or in 
their responsiveness to TGF-132, may contribute to the 
pathogenesis of metabolic bone disease. 
N 
'ORMAL skeletal morphogenesis relies upon the co- 
ordinated  activities  of multiple  cell  types.  The 
principal cell types in bone are osteoblasts, which 
are  of mesenchymal origin and synthesize bone  matrix, 
and osteoclasts, which are derived from the hematopoietic 
system and resorb bone. During development and adult 
life, osteoblasts and osteoclasts continuously replace old 
bone with new bone through a  process termed bone re- 
modeling (for a review see Parfitt, 1994). Bone remodeling 
occurs through discrete cycles of localized resorption fol- 
lowed by new bone synthesis in resorbed areas. The coor- 
dinated  nature  of these  cycles  implies  the  existence  of 
mechanisms that couple osteoblastic bone formation to os- 
teoclastic bone  resorption  in  a  site-specific manner and 
link the remodeling cycle to the local differentiation of os- 
teoblasts and osteoclasts from their respective precursor 
populations. By matching resorption with formation, bone 
remodeling normally maintains skeletal integrity and pre- 
serves bone mass and shape. 
The failure to coordinate osteoclastic bone resorption 
with  osteoblastic  bone  deposition  results  in  metabolic 
bone disease. In many cases, such as osteoporosis and hy- 
perparathyroidism, this failure leads to a progressive net 
loss of bone mass with time. The nature of the bone re- 
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modeling defects observed in various bone diseases sug- 
gests that distinct components of the remodeling cycle, in- 
cluding  the  frequency  and  extent  of  osteoclastic  bone 
resorption, as well as the rate of osteoblastic bone deposi- 
tion,  are  actively regulated  (Parfitt,  1983).  Several  sys- 
temic hormones are  known to influence bone turnover, 
and it is likely that they act through local factors present 
within  bone  (Mundy,  1993).  How  these  factors  control 
bone development and remodeling by locally regulating 
the  activity, differentiation, and  interactions of resident 
bone cells, is largely unknown. 
Several lines of evidence have  suggested that the  se- 
creted polypeptide transforming growth factor-t3 (TGF-[3) 
could be involved in the local regulation of skeletal devel- 
opment and turnover (for a  review see  Centrella et al., 
1994).  High concentrations of all three TGF-13 isoforms 
(TGF-131, TGF-132, and TGF-[33)  can be  extracted from 
mineralized bone matrix, and TGF-[3 is synthesized by os- 
teoblasts  and  osteoclasts  in  vivo  (Seyedin  et  al.,  1985; 
Robey et  al.,  1987; Sandberg et  al.,  1988; Pelton et  al., 
1991). TGF-13 has potent effects on bone cells in vitro and 
in vivo. Local injection of TGF-13 under the periosteum 
stimulates cartilage and bone formation (Noda and Camil- 
liere, 1989; Joyce et al., 1990),  and systemic injection of 
TGF-[32 leads to a generalized increase in osteoblastic ac- 
tivity (Rosen et al., 1994). In vitro, TGF-[3 induces extra- 
cellular  matrix  secretion  by  osteoblasts,  inhibits  matrix 
mineralization, and modulates osteoprogenitor cell prolif- 
eration and the expression of osteoblastic differentiation 
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trella et al., 1994). Results, however, have varied substan- 
tially depending upon the cell system. The effects of TGF-[3 
on osteoclast differentiation and bone resorption are also 
complex and may be indirectly modulated through nonos- 
teoclastic  cell  types  (Hattersley  and  Chambers,  1991). 
Neonatal and fetal organ culture studies have generally in- 
dicated that TGF-~3 inhibits osteoclast differentiation from 
bone marrow monocytes, yet stimulates bone resorption 
by differentiated osteoclasts (Tashjian et al., 1985; Chenu 
et  al.,  1988; Pfeilschifter et  al.,  1988; Dieudonn6  et  al., 
1991; Hattersley and Chambers, 1991). 
The normal role  of TGF-~  in bone  development has 
been hard to infer from these studies. Besides its complex 
and variable effects on bone cell populations in vitro and 
in vivo, a  given experimental result with TGF-~ may be 
potentially relevant to many different aspects of skeletal 
morphogenesis, including the generation of bone shape, 
bone growth, or bone remodeling. Furthermore, the exog- 
enous application of TGF-[3  does not mimic its route of 
production within bone. Osteoblasts produce TGF-~ largely 
as a bone matrix-bound latent complex that may be unable 
to  induce  cellular  responses  unless  first  released  from 
mineralized bone during osteoclastic bone resorption (Pfeil- 
schifter and Mundy, 1987). Lastly, the short term nature of 
TGF-~ administration in both in vitro and in vivo experi- 
ments precludes an evaluation of the skeletal actions of 
TGF-~ at steady state. 
To gain more direct insight into the role of TGF-~3 in 
bone morphogenesis, we generated transgenic mice that 
overexpress active TGF-~32 specifically in bone. Increased 
synthesis of TGF-132 in osteoblasts  leads to  a  dramatic, 
age-dependent loss of bone mass. This phenotype is attrib- 
uted to a primary defect in bone remodeling, associated 
with increased  activities of both  osteoblasts  and  osteo- 
clasts. Our results implicate TGF-[3 and more specifically 
TGF-132 as an important local regulator of bone remodel- 
ing in vivo and raise the possibility that altered TGF-~32 
expression or responsiveness may underlie the local patho- 
genesis of osteoporosis,  hyperparathyroidism, and other 
metabolic bone diseases. 
Materials and Methods 
Expression Plasmid 
PCR mutagenesis was performed on the human TGF-132 cDNA (de Mar- 
tin et al., 1987) to replace cysteine codons 226 and 228 in the TGF-132 pre- 
cursor with codons TCT and AGC for serine, and to introduce a 5' EcoRI 
site  (preceding nucleotide  178)  and  a  3'  BamHI site  (after  nucleotide 
1426)  to allow subcloning. The resulting fragment was sequenced to con- 
firm that no other point mutations were introduced during PCR amplifica- 
tion. The expression plasmid pOc-132C2S2, cloned into pcDNAII (Invitro- 
gen, San Diego, CA), consisted of a 1.8-kb fragment of the rat osteocalcin 
promoter (Baker et al., 1992),  followed by a 0.65-kb fragment spanning 
the rabbit 13-globin second intron (O'Hare et al., 1981), the mutated 1.3-kb 
TGF-132 cDNA fragment and a  0.63-kb fragment of the human growth 
hormone  gene  to  allow  polyadenylation.  Mature  human TGF-132  ex- 
pressed by pOc-132C2S2  has 97% amino acid sequence identity to mouse 
TGF-132  (Miller et al., 1989).  To verify that this plasmid could express 
TGF-132, it was transfected into ROS 17/2.8 osteosarcoma cells using the 
Ca2PO4 precipitation method. As a control, cells were transfected with a 
plasmid expressing 13-galactosidase under control of the osteoealcin pro- 
moter. Tissue culture supernatant was collected 72 h  after transfection, 
concentrated 10-fold on a Centricon C-10 column (Amicon, Inc., Beverly, 
MA),  and  assayed  by  TGF-132  ELISA  (Amersham  Corp.,  Arlington 
Heights, IL). 
Transgenic Mice 
DBA2  ×  C57BL/6  F1  (B6D2  FI)  mice  (Jackson  Laboratories,  West 
Grove, PA) were used to generate transgenic mice using standard tech- 
niques (Hogan et al., 1986).  We injected the osteocalcin-TGF-132 expres- 
sion insert excised as a 4.4-kb BamHI fragment from pOc-132C2SZ  and 
purified by Geneclean (Bio 101).  Transgenic mice were identified using 
Southern blot analysis of tail DNA (Laird et al., 1991)  using the 13-globin 
intron fragment as a  hybridization probe. Transgenic lines were estab- 
lished and maintained on a B6D2 F1 background, and subsequent genera- 
tions of transgenic animals were identified by nonradioactive dot blot us- 
ing either the 13-globin intron or growth hormone poly(A) fragments as 
probes. Nonradioactive hybridization reagents were purchased from Boehr- 
inger Mannheim (Indianapolis, IN) and used as described (Engler et al., 
1993). 
RNA Analysis 
Total bone RNA was isolated from 4-5 wk-old animals. Femurs and hu- 
meri were dissected and cleaned of soft tissues. Epiphyses were cut off, 
and the bone marrow was flushed out with PBS. Bones were then crushed 
in a mortar in liquid nitrogen, and further homogenized on ice in an Omni 
2000 tissue homogenizer (Omni International, Marietta, GA) for 30 s in 4 
ml Ultraspec RNA isolation reagent (Biotecx, Houston, TX). RNA was 
purified according to  the manufacturer's instructions, and treated  with 
RQ1  DNAase  (Promega,  Madison,  WI)  before  further  analysis.  One 
mouse typically yielded 25-40 p.g total bone RNA. 
Total bone RNA from two mice from each transgenic line was analyzed 
for  the  presence of spliced transgene mRNA by  reverse-transcriptase 
PCR (RT-PCR). Reverse-transcriptase (RT) 1 reactions were performed 
on 500-800 ng RNA in 20 I~1 of 1 ×  PCR buffer (GIBCO-BRL, Gaithers- 
burg, MD), 2.5 mM MgCl  2, 1 mM dNTPs, 100 pmol random hexanucle- 
otides (Pharmacia LKB Biotechnology, Piscataway, NJ), 1 mM DT'L 0.5 
p~l RNasin (Promega), and 1 Ixl MMTV reverse transcriptase (GIBCO- 
BRL). Control reactions without reverse transcriptase were done in paral- 
lel. RT reactions were incubated for 10 min at room temperature, 30 min 
at 37°C,  30 min at 42°C, and then stored directly at 4°C. To detect the 
spliced transgene cDNA by PCR, the 5' primer (5'-TCCTGAGAACT- 
TCAGG/CTCCTG-3')  spanned the rabbit  13-globin intron  splices sites 
and  the  3'  primer  (5'-CCTTGGCGTAGTACTCTTCGTC-3') was  lo- 
cated within the TGF-132 cDNA, to yield an expected product of 378 bp. 
1 ixl of RT reaction was amplified by PCR cycling in a 50-1xl reaction vol- 
ume containing 1×  PCR buffer (GIBCO-BRL),  3 mM MgCI  2, 0.2 mM 
dNTPs, 0.1% Triton X-100, 10 pmol each primer, and 0.25  I-d Taq poly- 
merase (GIBCO-BRL). 20 ILl of the reaction was run on a 2% TBE agar- 
ose gel stained with ethidium bromide. To confirm that the resulting DNA 
bands corresponded to TGF-132 cDNA, we performed Southern blot hy- 
bridization using a human TGF-132 cDNA fragment as probe. As a control 
for RNA quality and successful RT reactions, 1 p,1 of each RT reaction 
was amplified using primers specific for the osteocalcin gene (Araki et al., 
1993) in 1.5 mM MgCI2. 
Preparation of Bone Extracts 
Bone extracts were prepared as described (Finkelman et al., 1991)  with 
modifications, from 35-d-old transgenic and nontransgenic females. Fe- 
murs and humeri were cleaned of soft tissue and the epiphyses and bone 
marrow were removed. Bones were stored at  -70°C. To prepare  bone 
powder, bones were crushed in a mortar in liquid nitrogen and fat was re- 
moved as described (Finkelman et al., 1991), yielding 15-30 mg bone resi- 
due. Bone powder was then extracted for 36 h at 4°C in 300 ~l extraction 
buffer (4 M  guanidine hydrochloride, 10% EDTA, 30 mM Tris-HC1 pH 
7.4) containing 5 p.g/ml aprotinin, 5 I~g/ml leupeptin, and 1 mM PMSF, 
with constant rotation. After removal of the debris by 15 min centrifuga- 
1. Abbreviations used in this paper: Ccd, cleidocranial dysplasia; PTH, para- 
thyroid hormone; RT, reverse-transcriptase. 
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tein concentration using the Bradford assay (Biorad Labs., Hercules, CA). 
Determination of TGF-fl Protein Concentrations 
TGF-IM and TGFq32 concentrations were quantitated using TGF-13I- and 
TGF-132-specific ELISA kits (R&D Systems, Minneapolis, MN and Am- 
ersham Corp., respectively), according to the manufacturers' instructions. 
All bone samples were assayed in duplicate. 
In bone samples, TGF-13 was already activated due to the protein ex- 
traction in guanidine-HCl and did not require further acid-activation be- 
fore ELISA. However, to assay TGF-13 in culture media and plasma, sam- 
ples were acid-activated (Lawrence et al., 1985)  by an addition of 1/10th 
vol of 1.2 N HC1 at room temperature and neutralized after 20 min by ad- 
dition of 1/5th vol 0.72 N NaOH, 0.5 M Hepes. 80 txl of plasma were as- 
sayed per mouse, with two mice per test group, and five control mice. Ac- 
tive and latent TGF-132  levels in cell culture media were  assayed using 
duplicate samples either treated or untreated with acid. 
Serology, Body Weights 
Serum was collected by eye bleeds from 3 sex-matched transgenic and 3 
nontransgenic littermates per age group. Calcium, phosphorous, total pro- 
tein, and creatinine were determined by automated protocols (California 
Veterinary Diagnostics, Inc., West Sacramento, CA). Heparinized tubes 
were  used for the collection  of plasma. Weights of juvenile mice were 
measured from several groups of 2-3 transgenic and nontransgenic sex- 
matched littermates. 
X-ray Analysis 
After sacrifice by CO2 inhalation, radiographs were taken on a  faxitron 
model  43805  N  (Hewlett-Packard,  Palo  Alto,  CA),  using  Kodak 
X-OMAT TL film. Exposure was for 1 rain at 35 kVp. For 35-d-old mice, 
a total of 16 D4, 7 D5 mice, and 13 control littermates were analyzed. For 
5-11-month-old males and virgin females, a total of 7 D4 and 8 D5 mice, 
as well as 20 control littermates and nonlittermates were analyzed. Consis- 
tent results were obtained from mice of the same line and age. 
Histology and TGF-fl2 Immunohistochemistry 
For paraffin-embedded sections, bones were fixed at 4°C in 2% paraform- 
aldehyde/PBS, and decalcified for 4 h in 22.5% formic acid, 10% sodium 
citrate at room temperature. 5 o.m sections were stained with hematoxylin 
and eosin for routine analysis using established procedures (Sheehan and 
Hrapchak, 1980).  For each age group, 2-3 bones per mouse from at least 
2-5 mice of each line were analyzed. Serial cross sections of tibia were 
standardized in reference to the hypertrophic cartilage-metaphyseal junc- 
tion, defined as the cross section with an area occupied by 50%  hyper- 
trophic cartilage and 50% primary spongiosa. 
Anti-TGF-132 immunohistochemistry  was performed as modified from 
Pelton et al. (1991) using rabbit anti-TGF-132 (kindly supplied by Dr. Les- 
lie Gold, New York University Medical School) at a concentration of 2.5 
p~g/ml. An HRP-conjugated donkey anti-rabbit secondary antibody (Am- 
ersham) was used at a 1:100 dilution. Diaminobenzidine was used as sub- 
strate for the HRP reaction and the sections were counterstained with he- 
matoxylin. 
For osteoclast detection using histochemical staining for tartrate-resis- 
tant acid phosphatase (TRAP) activity, femurs fixed in 2% paraformalde- 
hyde/PBS were decalcified for 3 d at 4°C in 10% EDTA, 0.1 M  Tris, pH 
6.95,  embedded in Tissue-Tek OCT compound, and sectioned at 10 ~m. 
After equilibration in 0.2 M  sodium acetate, 50 mM sodium tartrate, pH 
5.0, for 20 min at room temperature, sections were incubated for 17 min at 
37°C in the same buffer containing 0.5 mg/ml naphthol AS-MX phosphate 
(Sigma Chem. Co., St. Louis, MO) and 1.1 mg/ml Fast Red Violet LB salt 
(Sigma). Sections were counterstained in methyl green. 
To detect  bone mineralization, 4  l~m undecalcified longitudinal sec- 
tions of the tibia  (see below) were stained by the yon Kossa technique 
(Sheehan and Hrapchak, 1980) and counterstained with toluidine blue. 
Quantitative and Kinetic Analyses 
Trabecular surface density was calculated by a stereological method using 
transverse lines superimposed upon bone section micrographs (Weibel, 
1969).  From longitudinal sections of the proximal tibial metaphysis, data 
were collected from the entire area of the bone marrow cavity 200-1,800 
~m from the growth plate for 35-d-old mice, and 0-1,600 ixm from the 
growth plate for 7-ll-month-old mice. Values represent the mean _+ stan- 
dard deviation of the surface density calculated from at least three non- 
consecutive sections per mouse from 3 D4, 2 D5, and 3 nontransgenic lit- 
termate 35-d-old mice, and 2  D4, 2  D5,  and 4  control  7-11-month-old 
mice. 
Data  for  osteocyte density,  and  osteoblast  and  osteoprogenitor  cell 
number were taken from cortical bone cross sections of the proximal tibia, 
2.5-3.1 mm from the growth plate. Osteocyte density was calculated as the 
3:2 power of the two-dimensional density in cross section, and osteoblast 
and osteoprogenitor cell number was calculated as the square of the one- 
dimensional density on the endosteal surface. Values represent the mean 
_+ standard deviation of 30-70 measurements per group of 2 D4 and 3 lit- 
termate control mice. Standard deviations maintain the same percent er- 
ror of the original lower-dimensional value. The rate of osteocyte differ- 
entiation was calculated as the product of the osteocyte density and the 
bone volume produced per day in a mm  2 unit area (the mineral apposition 
rate multiplied by the mm  2 unit area). 
For the kinetic analyses, 31 day sex-matched transgenic and nontrans- 
genic littermates were given intraperitoneal injections of 2.5 mg/kg cal- 
cein, followed by similar injections of 25 mg/kg tetracycline 3 d later. Mice 
were sacrificed at day 35, and their bones were fixed in 70% ethanol at 
4°C. Before processing for undecalcified sectioning, bones were prestained 
using the Villanueva bone  stain  (osteochrome stain, Polysciences Inc., 
Niles, IL) for 3 d at 4°C. Matched bones were dehydrated and embedded 
with identical orientation in methylmethacrylate, sectioned at 4 i.Lm, and 
viewed under UV light. 
Since there was virtually no trabeculation in bones from D4 animals, in- 
cluding the vertebrae, data for the mineral apposition rate and mineraliza- 
tion lag time was taken from epiphyseal and diaphyseal endosteal surfaces 
of the tibia. Individual measurements for the mineral apposition rate were 
calculated as the distance between the double fluorochrome labels divided 
by 3 d, and for the mineralization lag time as the osteoid seam width di- 
vided by the mineral apposition rate at the same location. Values represent 
the mean _+ standard deviation of 40-80 measurements per group of 2 D4 
and 2 littermate control mice. 
Cleared Skeletal Preparations 
Cleared skeletons stained with alizarin red or alcian blue staining were 
prepared as adapted from Kaufman (1992). We analyzed four litters of D4 
male x  B6D2 F1  female crosses, giving a  total of 19 transgenic and 16 
nontransgenic embryonic day 15.5 and 2-d-old offspring. 
Results 
TGF-fl2 Expression under the Control of the 
Osteocalcin Promoter 
We designed the plasmid pOc-132C2S2 to drive the osteo- 
blast-specific expression of biologically active TGF-[32 in 
transgenic mice (Fig.  1 a). Among the three isoforms of 
TGF-[3, we elected to express TGF-132 because it is nor- 
mally expressed by osteoblasts and is thought to be more 
active than TGF-131 in inducing cartilage and bone forma- 
tion (Seyedin et al., 1985; Joyce et al., 1990). TGF-[3 is nor- 
mally made in a latent or biologically inactive form due to 
noncovalent interactions between its large precursor seg- 
ments and the mature TGF-13 homodimer (Centrella et al., 
1994).  To assure  the  secretion and  availability of active 
TGF-132, we introduced two point mutations that resulted 
in the replacement of cysteines at positions 226 and 228 in 
the TGF-132 precursor segment by serines. Similar muta- 
tions of the corresponding cysteines in the TGF-131 precur- 
sor (at positions 233 and 235) have been shown to lead to 
the spontaneous activation of a fraction of the TGF-13 se- 
creted by transfected cells in culture, presumably as a re- 
Erlebacher and Derynck Transgene Overexpression of TGF-fl2 in Bone  197 suit of destabilization of the interactions between the pre- 
cursor segments and the active TGF-13 dimer (Brunner et 
al., 1989). 
To  achieve  specific transgene  expression  in  bone,  we 
used a  1.8-kbp fragment of the  rat osteocalcin promoter 
previously shown to direct osteoblast-specific expression 
(Baker et al., 1992). Osteocalcin is an abundant bone ma- 
trix protein specifically expressed by mature osteoblasts, 
but  not  by osteoprogenitor cells (Bronckers  et al.,  1985; 
Groot et al., 1986).  We verified the expression of TGF-~2 
from pOc-[~2C2S2  after transfection  of the  plasmid into 
the osteocalcin-expressing osteosarcoma cell line ROS 17/2.8. 
The double cysteine to serine mutation caused spontane- 
ous  activation of ~10%  of the  total  amount  of secreted 
TGF-132 (data not shown). 
Figure 1.  Generation and biochemical  characterization  of trans- 
genic  mice.  (A)  Schematic  presentation  of the  plasmid  pOc- 
[~2C2S2 expressing the human TGF-1~2  with cysteines at positions 
226 and 228 within  the precursor segment replaced by serines. 
The direction  of transcription  and the position of the primers for 
RT-PCR analysis are indicated.  (B) RT-PCR analysis of trans- 
gene mRNA expression  from bone RNA. The RT-PCR gener- 
ated eDNA fragment was subjected  to Southern blot analysis us- 
ing a human TGF-132 eDNA probe. The four lines that express 
the transgene mRNA are shown, and a and b represent two dif- 
ferent mice of each line. Abbreviations:  NT, nontransgenic;  RT, 
reverse-transcriptase.  (C) Quantitation of TGF-132 levels in bone 
matrix  of 35-d-old  female mice.  TGF-132 concentrations  were 
measured by TGF-132 ELISA and normalized to total extracted 
protein concentration.  The graph represents the mean and stan- 
dard deviations  of duplicate  measurements of two animals  per 
transgenic line and four nontransgenic  littermates. 
Transgenic Mice Overexpressing  TGF-fl2 in Osteoblasts 
We established eight independent transgenic lines in which 
the  transgene  of pOc-~2C2S2  was stably integrated  into 
the genome (data not shown). Four of these lines expressed 
the  transgene  mRNA  as  evaluated by RT-PCR of bone 
mRNA (Fig.  1 b). The two mouse lines with the  highest 
mRNA levels, D4 and D5, were chosen for detailed char- 
acterization. In contrast to the D5 line, we were unable to 
generate homozygous D4 animals, presumably as a result 
of intrauterine  or perinatal death. We assessed transgene 
expression at the protein level using a  specific ELISA to 
quantitate the TGF-~2 extractable from bone. Bone pow- 
der extracts from hemizygous D4 and D5 mice contained 
16-  and  2.5-fold  more TGF-[~2 than  bone  extracts  from 
nontransgenic mice, as normalized to total extracted pro- 
tein (Fig. 1 c). The use of guanidine hydrochloride, which 
activates TGF-[32 in this extraction procedure, did not al- 
low us to determine what fraction of the extracted TGF-~2 
was active in situ. A TGF-[~l-specific ELISA revealed that 
control bones contained 7.5-fold more TGF-[31 than TGF-[32 
(data not shown). The level of TGF-131  was unaltered in 
extracts of D5 bones, but was ~40% lower in D4 bones. 
To  localize  the  cellular  sites  of  synthesis  of  TGF-132 
within bone, we stained longitudinal sections of the tibia of 
35-d-old D4 mice with a  TGF-~2-specific antibody.  Sec- 
tions of transgenic bone showed a distinct increase in the 
TGF-132  immunoreactivity  of  osteoblasts  as  compared 
with control sections (Fig. 2). The increased immunoreac- 
tivity was very pronounced  in  the  osteoblasts lining epi- 
physeal bone surfaces (Fig. 2 b, open arrows), but not in 
osteoblasts within the metaphysis (data not shown). In ac- 
cordance with the osteoblast-specific expression of the os- 
teocalcin promoter, there was no increase in the low level 
of endogenous TGF-132  staining in bone marrow cells. In 
addition, both transgenic and control sections showed sim- 
ilar levels of strong endogenous TGF-132  immunostaining 
in  megakaryocytes (Fig.  2,  a  and  b, arrows),  osteoclasts 
and articular chondrocytes, and moderate immunostaining 
in hypertrophic chondrocytes (Fig. 2 and data not shown). 
Macroscopic Evaluation of the Skeletal Phenotype 
X-ray analysis revealed multiple skeletal defects in young 
mice of the  high-expressing D4  line  (Fig.  3).  At 35  d  of 
age, hemizygous D4 mice had a dramatic decrease in bone 
density  (osteopenia)  compared to  normal littermates,  as 
revealed by the  generally radiolucent  appearance  of the 
entire skeleton (compare Fig. 3, b and d with a and c) and 
the dramatic reduction in trabecular bone particularly evi- 
dent in the metaphyses of long bones (Fig. 3, a  and b, ar- 
rows). Furthermore, the cortices of long bones were thin- 
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in bone. Sections are through the proximal epiphysis of the tibia 
from 35-d-old nontransgenic  littermate (A) and D4 transgenic  (B 
and C) females.  C serves as a control of B in which the primary 
antibody against TGF-132 is omitted from the staining procedure. 
The  use  of diaminobenzidine  as  a  substrate  results  in  brown 
staining for TGF-[32. Sections are counterstained with hematoxy- 
lin (blue).  Transgenic bone shows strong TGF-132 immunoreac- 
tivity in osteoblasts lining the endosteal surfaces (open arrows) in 
contrast to the low level of immunoreactivity within similar os- 
teoblasts in nontransgenic bone (,4). Endogenous TGF-132 stain- 
ing  is  seen  in  articular  chondrocytes  (a)  and  megakaryocytes 
(closed arrows). A low level of staining is seen in the bone mar- 
row of both sections. Note also the increased  number of plump, 
mature osteoblasts lining  the  surfaces  of transgenic  bone  (B). 
Scale  bar shows  100  vLm. Abbreviations:  a,  articular chondro- 
cytes; b, bone. 
ner than normal and frequently contained multiple internal 
radiolucent  defects  (Fig.  3  b,  arrowheads).  Fracture  cal- 
luses were regularly observed in long bones (Fig. 3 b, aster- 
isk), and callus-like focal lesions were frequently observed 
in the extremities, particularly at the distal ends of the ra- 
dius,  ulna,  tibia,  and  fibula  (data  not  shown).  Based  on 
their location and ultimate healing with time, these distal 
lesions most likely corresponded  to stress fractures.  The 
increased fragility of transgenic bones was also evident by 
the ease with which  they were broken during dissection. 
By  7  months,  hemizygous  D4  mice  were  extremely os- 
teopenic, with a  glassy appearance of the entire skeleton 
(compare Fig. 3 fwith 3 e), a virtual absence of trabecular 
bone  inside  long bones  (arrows),  and  a  strikingly  lower 
level of trabecular bone in the vertebrae. Soft tissue calci- 
fications  were  apparent  in  the  necks  of aging  D4  mice 
(1-yr-old).  Lastly, whereas all other bones had generally 
normal shapes and sizes, all D4 mice lacked normal clavi- 
cles and only small vestiges of their distal ends were appar- 
ent (Fig. 3, c and d, arrows). This aspect of the D4 pheno- 
type will be described in more detail below. 
The D5 line had a considerably milder phenotype than 
the D4 line, consistent with its much lower level of TGF-t32 
overexpression.  Young  (35  d)  hemizygous and  homozy- 
gous D5 mice did not have any obvious defects detectable 
by X-ray analysis; however, by 7 months of age, hemizy- 
gous D5 mice had a dramatic reduction of trabecular bone 
in the metaphyses of long bones (Fig. 3 g, arrow)  and in 
the vertebral bodies, particularly of the lower thoracic and 
upper lumbar regions (data not shown). The skeletal ab- 
normalities in both lines were similar in males and virgin 
females. 
Aside  from  these  abnormalities,  transgenic  mice  ap- 
peared generally healthy. The mortality rate and fertility 
of transgenic animals were similar to wild type. All visceral 
organs appeared grossly normal at autopsy. 35-d-old mice 
had normal body weights, tooth eruption was not delayed, 
and  teeth  appeared  normal.  Importantly, the  lengths  of 
long bones, an indication of longitudinal growth, were also 
normal. Only with increasing age did the body weight of 
D4  mice  decrease  in  comparison  to  normal  littermates 
(~60% of normal in 6-month-old D4 mice). 
Based on various blood serum tests, there was no indica- 
tion  of a  general  metabolic disease  in  the  high  overex- 
pressing  D4  line.  No  differences  in  serum  calcium  and 
phosphorus levels were apparent between 35-d-old trans- 
genic and control mice, while 6-month-old transgenic ani- 
mals had  normal serum phosphorus,  low serum calcium, 
and normal serum protein levels (data not shown). These 
results indicate that D4 mice did not have primary hyper- 
parathyroidism or a humoral hypercalcemia syndrome, yet 
had a low circulating calcium level at older ages. Normal 
serum creatinine levels at 6 months of age excluded renal 
failure.  Plasma TGF-132  levels were  normal in  D5  mice, 
but were elevated 3--4-fold in 35-d-old D4 mice, to ~2 ng/ 
ml. At this level, circulating TGF-~ is not physiologically 
relevant since it is inactivated by the abundant serum pro- 
tein  et2-macroglobulin  (O'Connor  and  Wakefield,  1987; 
Huang et al., 1988).  Taken together, our analyses support 
the  notion  that  the  observed  skeletal  abnormalities  re- 
suited  from the localized overexpression of TGF-132  and 
not from a general endocrine disturbance.  It is likely that 
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tibia of 35-d-old wild type (A), D4 (B), and homozygous D5 (C) males. As compared with nontransgenic  bone (A), D4 bone shows a 
thinned cortex and reduced trabeculation, dramatically in the metaphysis and moderately in the epiphysis (B). In the metaphysis, trans- 
genic trabecular bone is apparent only in the immediate area of the growth plate, whereas in nontransgenic  bone it extends down the 
length of the bone marrow cavity towards the diaphysis (arrows).  In contrast to D4 bone, D5 bone (C) appears histologically normal at 
this age. The epiphyseal growth plates in both the D4 and D5 sections appear normal. (D-F) Longitudinal  sections through the proximal 
tibia of 7-month-old wild type (D), D4 (E), and hemizygous D5 (F) males. Cortical bone thinning  and the extreme reduction in trabecu- 
lar bone mass at this age is evident in D4 bone (E), as compared with nontransgenic  bone (D), with a complete loss of trabeculation in 
the metaphysis and a dramatic reduction of trabeculation in the epiphysis. The residual growth plate cartilage is also more eroded in the 
D4 section (arrow) than in nontransgenic  bone. In contrast to the normal phenotype in D5 bone at 35 d, 7-month-old bone shows a com- 
plete loss of metaphyseal trabeculation and a moderate reduction in epiphyseal trabeculation (F), although clearly not as severe as in D4 
bone. Abbreviations:  e, epiphysis; g, growth plate; m, metaphysis; d, diaphysis; c, cortical bone. Decalcified,  paraffin-embedded sections 
were stained with hematoxylin and eosin. Scale bar shows 400 ~m. 
Figure 3.  X-ray analysis of transgenic mice. (A and B) Radiographs of the pelvis, tibia, and femur of 35-d-old nontransgenic  littermate 
(A) and D4 transgenic (B) males. Transgenic  bone is generally more radiolucent, and long bones show a dramatic reduction of metaphy- 
seal trabeculation (arrows)  and thinned cortices pockmarked with multiple radiolucent defects  (arrowheads).  There is also a fracture of 
the tibia and fibula (asterisk),  with a clear fracture callus formed around the tibia. Scale bar shows 0.4 mm. (C and D) Radiographs of 
the upper thorax of 35-d-old nontransgenic  littermate (C) and D4 (D) males. Only distal vestiges of clavicles are visible in the transgenic 
skeleton (arrows).  As with B, transgenic bone is more radiolucent than normal, and intracortical defects in the humerus are also appar- 
ent. The wild-type mouse shows an anterior arch of the atlas, a variable feature of normal mice. Scale bar shows 0.5 mm. (E-G) Radio- 
graphs of the pelvis, proximal tibia, and femur of 7-month-old nontransgenic  (E) and D4 (F) and D5 transgenic (G) males. D4 bone (F) 
has an overall glassy appearance with a virtual absence of metaphyseal trabeculation, markedly reduced epiphyseal trabeculation, and a 
thinned cortex. Radiographic changes are much milder in D5 mice than in D4 mice and only a marked reduction in metaphyseal and ep- 
iphyseal trabeculation is apparent (G). Arrows show areas of metaphyseal trabeculation in the distal femur. Scale bar shows 0.4 mm. 
Erlebacher and Derynck  Transgene Overexpression of TGF-~2 in Bone  201 Figure 5.  Histological appearance of transgenic bone. (A and B) Cross sections of the tibia of 35-d-old nontransgenic littermate (A), and 
D4 transgenic (B) males, 3.0-3.1  mm distal to the proximal epiphyseal growth plate. In contrast to smooth endosteal and periosteal sur- 
faces characteristic of diaphyseal bone in nontransgenic bone, D4 bone shows extensive periosteal and more pronounced endosteal re- 
sorption. In addition, cortical bone is more porous than normal (arrows), and the periosteal and endosteal surfaces of D4 bone are ex- 
tremely fibrotic. Scale bar shows 400 I~m. (C-E) Cross sections of the tibia of 35-d-old nontransgenic (C), and D4 (D), and homozygous 
D5 (E) males, 3.0-3.1  mm distal to the proximal epiphyseal growth plate. Sections show equivalent areas of the tibia; C and D are high 
power views of areas in A and B. The dramatic increase in cellularity of D4 bone (D) as compared with normal bone (C) is evident from 
the increased density of osteocytes within bone matrix and the increased number of presumptive fibroblastic osteoprogenitor ceils (op) 
which give rise to the osteoblasts (ob) lining the endosteal and periosteal surfaces.  Abundant extracellular matrix contributes to the fi- 
brotic appearance of the endosteum and periosteum. A resorption lacuna extending deep within cortical bone is marked (closed arrow). 
Areas of prior resorption refilled with new bone matrix (lightpink) are apparent at the bone surface under the periosteum, where a scal- 
loped cement line demarcates new from old bone (open arrow). Similar areas are also apparent deep within cortical bone and on nonre- 
sorbed endosteal surfaces.  In contrast to D4, D5 bone (E) shows no detectable histological alterations from wild type. Scale bars show 
100 p.m. Abbreviations: b, cortical bone, m, bone marrow, e, endosteum, p, periosteum. Decalcified, paraffin-embedded sections were 
stained with hematoxylin and eosin. 
The Journal of Cell  Biology,  Volume 132, 1996  202 Figure 6.  Histochemical identification of osteoclasts. Sections of metaphyseal trabeculation  and growth plate of femurs from 35-d-old 
nontransgenic  littermate (A) and D4 (B) females, stained for tartrate-resistant  acid phosphatase  activity (red), an osteoclast-specific 
marker.  The numbers  of osteoclasts in sections of control and transgenic bone are similar. Sections are counterstained  with methyl 
green. Scale bar shows 200 I~m. 
the hypocalcemia, low body weight, and soft tissue calcifi- 
cations  observed  in  the  older  D4  mice  were  secondary 
manifestations of prolonged bone disease. 
Histological Appearance of Transgenic Bone 
The progressive loss of bone mass in our overexpressing 
lines noted by X-ray was also apparent histologically (Fig. 
4). When compared to sections of nontransgenic littermate 
controls at 35  d  (Fig. 4 a), longitudinal sections through 
the proximal tibia of D4 mice (Fig. 4  b)  revealed a  thin 
cortex and a dramatic loss of trabeculation. In the meta- 
physis, trabecular surface density was reduced 70%, from 
13.6 (_+1.4) mm2/mm  3 in controls to 4.2  (___2.5) mm2/mm  3. 
Surprisingly, the epiphyseal growth plate, which is respon- 
sible  for  longitudinal  growth,  appeared  normal.  Similar 
longitudinal  sections  of the  tibia  from  7-month-old  D4 
mice revealed a complete absence of metaphyseal trabecu- 
lation (with a reduction in surface density from 5.2 (---1.3) 
mm2/mm  3 in controls to 0 mm2/mm3),  very little remaining 
epiphyseal trabeculation, and extremely thin cortical bone 
(compare Fig.  4  e  with 4  d).  In contrast to the D4 line, 
hemizygous and homozygous D5 mice had only very mild 
alterations in phenotype at day 35 (Fig. 4 c, with a meta- 
physeal surface density similar to controls at 15.1  (+1.8) 
mm2/mm3),  yet 7-month-old hemizygous mice  showed  a 
complete absence  of metaphyseal trabeculation (0 mm2/ 
mm  3 surface density), and  dramatically reduced epiphy- 
seal trabeculation (Fig. 4 f). 
The  histological  appearance  of  transgenic  bone  sug- 
gested an increase in osteoclastic resorption. The epiphy- 
seal  plates  of 7-month-old  D4  mice  were  more  eroded 
than those of control mice (Fig. 4 e, arrow). At 35 d, corre- 
sponding cross-sections of the tibia at equivalent distances 
from the growth plate (Fig. 5) showed that cortical bone 
was more porous than normal and contained large resorp- 
tion lacunae lined by osteoblasts (Fig. 5 b, arrows). Fur- 
thermore,  endosteal  resorption  was  more  pronounced, 
and periosteal resorption, characteristic of the metaphysis, 
was  apparent  in  more  diaphyseal sections  of transgenic 
bone (Fig. 5, b and d). In equivalent diaphyseal sections of 
normal  bone,  the  periosteum  had  already  assumed  its 
Erlebacher and Derynck Transgene Overexpression of TGF-fl2 in Bone  203 Figure 7.  Mineralization of transgenic bone. Undecalcified sections of tibia from 35-d-old nontransgenic littermate (A and C) and D4 (B 
and D) females, stained by the von Kossa technique for calcium deposits (dark brown or black), and counterstained with toluidine blue. 
Longitudinal sections through the diaphysis reveal large unmineralized areas of cortical bone (osteoid, light blue) in transgenic bone 
(B), whereas wild-type bone is entirely mineralized (A). However, there is no difference in the minimal amount of osteoid present in the 
metaphyseal trabeculation adjacent to the growth plate (C and D). Scale bar shows 100 Ixm for A and B, 50 ixm for C and D. 
characteristically  quiescent  appearance  (Fig.  5,  a  and  c). 
Surprisingly,  no striking  differences  in  the  number  of os- 
teoclasts were observed between normal and D4 mice, as 
assessed by the  osteoclast-specific  histochemical  stain for 
tartrate-resistant  acid phosphatase activity (Fig. 6). 
Histological sections of 35-d-old D4 bone (Fig. 5 d) also 
revealed  marked  increases  in  osteocyte  density  (a three- 
fold increase  from 62,000  (---14,000)  cells/mm  3 to 197,000 
(+34,000)  cells/mm  3)  and  presumptive  osteoprogenitor 
cell  number  (a  fivefold  increase  from  22,000  (±8,000) 
cells/mm  2 bone  surface  to  120,000  (+_47,000)  cells/mm2), 
suggesting  increased  rates  of  osteoblastic  differentiation 
and  osteoprogenitor  cell proliferation.  The increased  cell 
number along with the associated increase in extracellular 
matrix  gave  many  cortical  bone  surfaces  a  distinctly  fi- 
brotic appearance.  Osteoblast cell number itself remained 
constant  at  28,000  (+_7,000)  cells/mm  2  bone  surface  in 
transgenic bone compared to 25,000 (±6,000)  cells/mm  2 in 
controls.  On epiphyseal and trabecular surfaces, however, 
osteoblasts  appeared  more  cuboidal  than  their  nontrans- 
genic counterparts  (Fig. 2 b, open arrows), consistent with 
active  bone  matrix  synthesis.  Osteocyte  density  was  also 
increased  in bone  from 7-month-old  mice, however bone 
surfaces at this age were not fibrotic. 
The mineralization of D4 bone was also abnormal. Bone 
matrix  synthesized  within  resorption  lacunae  frequently 
appeared  lightly stained  in decalcified  sections of cortical 
bone  from  both  35-d  (Fig.  5,  b  and  d)  and  7-month-old 
mice. This  matrix was unmineralized,  as shown  by unde- 
calcified  sections  stained  serially with  hematoxylin  or  by 
the  von Kossa technique,  which  reveals calcium  deposits 
as dark brown or black (Fig. 7). Large pockets of unminer- 
alized  matrix  extended  deep  within  cortical  bone  (light 
blue areas in Fig. 7  b), and probably corresponded  to the 
radiolucent  intracortical  defects  noted  by X-ray analysis. 
In addition, the osteoid seam, i.e., the new, as yet unminer- 
Figure 8.  Kinetic analysis of bone turnover. Undecalcified longitudinal sections of tibia from 35-d-old nontransgenic littermate (A and 
C) and D4 (B and D) males viewed under UV light.  Injection of calcein on day 31 and tetracycline on day 34 stains sequential sites of 
mineralization green and yellow, respectively. Counterstaining the sections with the Villanueva bone stain reveals unmineralized os- 
teoid as bright red. (A and B) Longitudinal sections through cortical bone of the diaphysis. Unlike the homogenous appearance and 
complete mineralization of nontransgenic bone (A), transgenic bone has many pockets of unmineralized osteoid (B, bright red). These 
areas are not bordered by either fluorochrome label, indicating that they were not mineralizing over the course of the experiment. In 
The Journal of Cell Biology,  Volume 132, 1996  204 contrast, the nonresorbed endosteal surfaces of both transgenic and nontransgenic  bone are mineralizing  as revealed by their double la- 
bels (arrows). Note the increased distance between the fluorochrome labels in transgenic bone. Scale bar shows 100 txm. (C and D) 
Higher power view of longitudinal  sections through the epiphysis adjacent to the growth plate (gp, deep purple). Fluorochrome labels in 
the transgenic section (D) are diffuse and irregular as compared with their smooth appearance in nontransgenic  bone (C). The distance 
between the labels as well as the width of the unmineralized  osteoid layer (bright red, arrowheads) is increased over the entire length of 
the transgenic bone surface, indicating  increased osteoblastic activity. Scale bar shows 100 i~m. 
Erlebacher artd Derynck  Transgene Overexpression  of TGF-~2 in Bone  205 Figure 9.  Cleared skeletal preparations of embryos and newborn mice. Nontransgenic  littermate (A-C) and D4 transgenic  (D-F) em- 
bryos and newborns stained with alizarin red to visualize mineralized  bone or alcian blue to visualize cartilage. (A and D) Neck area of 
embryonic day 15.5 nontransgenic  (A) and transgenic  (D) embryos stained with alizarin red to reveal mineralized  bone. Clavicles are 
fully formed in the wild-type embryo but appear as only distal rudiments in the transgenic  embryo (arrows). m, mandible.  (B and E) 
Neck area of 2-d-old nontransgenic  (B) and transgenic (D) pups stained with alcian blue. Mineralized bone is white and cartilage is blue. 
No cartilage rudiment links the hypoplastic clavicle in the transgenic pup with the sternum.  Arrowheads show the cartilage cap at the 
proximal end of the clavicle, which arises through a secondary induction  event (Tran and Hall, 1989). s, sternum.  (C and F) Forelimb 
paws of 2-d-old nontransgenic  (C) and transgenic (F) pups stained with alizarin red. The delay in ossification of the transgenic skeleton 
is apparent when corresponding  ossification centers are compared in transgenic and nontransgenic  paws. Furthermore, other skeletal el- 
ements have started to ossify in the control paw but not in the transgenic paw (arrows). 
alized layer of bone matrix deposited by osteoblasts, was 
wider on many nonresorbed endosteal surfaces in the epi- 
physis and diaphysis (see Fig. 8 d). In contrast, the miner- 
alization appeared normal in metaphyseal trabecular bone, 
where osteoid seams were absent in both transgenic and 
wild-type sections (Fig. 7, c and d). Under polarized light, 
unmineralized matrix displayed the typical pattern of bire- 
fringence associated with lamellar collagen fiber arrange- 
ment (not shown). 
The histological alterations seen in the long bones of D4 
mice were also evident in cross sections of parietal bones 
of the  skull,  which  develop via direct ossification rather 
than endochondral  ossification (data not shown). In con- 
trast to the D4 line, skeletal sections of hemizygous and 
homozygous D5 mice showed no microscopic histological 
alterations (see Fig. 5 e for a histological section of 35-d-old 
bone),  except  for  a  slightly  more  porous  appearance  of 
cortical bone (not shown). 
Kinetic Analysis of Bone Turnover 
We performed a  kinetic analysis of bone turnover to di- 
rectly  assess  the  synthetic  activity  of  osteoblasts  in  D4 
bone. Two fluorochromes that incorporate into bone ma- 
trix  at  sites  of mineralization  were  injected  into  young 
mice: calcein at 31 d of age, and tetracycline 3 d later, fol- 
lowed by a sacrifice of the animal the next day. Undecalci- 
fled bone sections viewed under  UV light visualized the 
incorporated fluorochromes as green and yellow fluores- 
cent lines labeling sites of mineralization at the  times of 
their injection. The distance between the two lines is thus a 
measure of the mineral apposition rate, which correlates 
with  the  local rate  of bone  matrix  deposition  by osteo- 
blasts (Parfitt, 1983).  Counterstaining of the sections with 
the  Villanueva  bone  stain  simultaneously visualized  un- 
mineralized osteoid by its red fluorescence. 
In long bones of 35-d-old control mice, the two fluoro- 
chrome labels formed smooth, contiguous and sharp lines 
(Fig. 8, a and c). In contrast, labels in transgenic bone were 
diffuse  and  irregular,  and  frequently  interrupted  by  os- 
teoid-filled resorption lacunae (Fig. 8, b  and d). The dis- 
tance between the two labels on many surfaces was also 
distinctly increased in comparison to normal bone (com- 
pare Fig. 8, a  and b  [arrows], and Fig. 8, c and d), corre- 
sponding to a  1.7-fold increase in the mineral apposition 
rate (from 2.3  [___0.3] ixm/day in controls to 4.0 [_1.0]  ixm/ 
day). Almost all nonresorbed endosteal surfaces of normal 
bones  were  labeled  with  both  fluorochromes, reflecting 
the overall growth of the skeleton at day 35, and the extent 
and  distribution  of these  surfaces were  similar in  bones 
from  D4  mice.  However,  the  pockets  of unmineralized 
matrix within cortical bone were not  labeled with either 
fluorochrome, indicating a severe mineralization defect of 
the  new bone matrix synthesized  within resorption lacu- 
nae (red areas, Fig. 8 b). While the unmineralized osteoid 
seam at endosteal surfaces was wider than normal (Fig. 8 
d, arrowheads), correlation of the osteoid seam width with 
the  mineral  apposition  rate  did  not  reveal  a  significant 
change in lag time of mineralization after osteoid deposi- 
tion (2.2 [+-0.7]  days in controls, 2.4  [-4-1.0] days in trans- 
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stricted to matrix synthesized within resorption lacunae. 
Absence of Clavicles and Delayed Ossification 
To further evaluate the skeletal development of D4 mice, 
we prepared cleared skeletons at different stages of devel- 
opment (Fig. 9). Skeletons were stained with alizarin red 
to visualize mineralized bone, or alcian blue to visualize 
cartilage.  At  embryonic day  15.5,  D4  clavicles were  al- 
ready clearly hypoplastic compared  to  normal  embryos 
(compare Fig. 9, d and a, arrows). Since clavicle develop- 
ment initiates at day 14-14.5 (Tran and Hall, 1989), this 
difference indicates a primary defect in clavicle formation, 
rather than secondary resorption. As expected for the nor- 
mal  pattern  of clavicle development through intramem- 
branous rather than endochondral ossification (Tran and 
Hall, 1989), no cartilage rudiment was observed connect- 
ing the clavicle vestige with the sternum (Fig. 9, b and e). 
Alizarin  red  staining  also  revealed a  general  delay in 
mineralization of the D4 skeleton, as illustrated by the os- 
sification pattern in the hands of 2-d-old mice (Fig. 9, c and 
f). Whereas the lengths of corresponding digits were iden- 
tical in transgenic and control mice, the mineralization of 
individual transgenic bones clearly lagged  behind corre- 
sponding bones of normal mice. In addition, some bones 
of transgenic mice were not yet mineralized when com- 
pared to control counterparts (arrows). Importantly, the 
cartilaginous  skeleton  of  transgenic  embryos  appeared 
normal, as evident from alcian blue stained preparations. 
With the exception of the clavicles, all other bones of D4 
mice appeared normal in size and shape. 
Discussion 
TGF-~3 is deposited in bone matrix and all three TGF-~ 
isoforms are expressed by bone cells in vivo. In vitro and 
in vivo studies have shown that TGF-13 can affect the activ- 
ity of both osteoblasts and osteoclasts. However, the com- 
plexity of these results has made it difficult to define the 
normal role of TGF-13 in bone development and turnover. 
To provide a physiological context to study the skeletal ac- 
tions  of TGF-13,  we  generated  transgenic mice in  which 
TGF-132 is  overexpressed specifically by osteoblasts. We 
characterized two independent lines:  D5  with  a  2.5-fold 
and D4 with a 16-fold increase in the amount of TGF432 
extractable from bone matrix. 
The primary phenotype of both lines was  progressive, 
age-dependent loss of bone mass, and the severity of the 
phenotype  correlated  with  the  expression  level  of  the 
transgene. D5 mice had no reduction of bone mass at day 
35, but showed a complete loss of metaphyseal trabecula- 
tion and dramatically reduced epiphyseal trabeculation by 
7 months. In contrast, bone loss in the D4 line was already 
striking at day 35 and extreme by 7 months. These mice 
also showed a  defect in clavicle development, a  general- 
ized delay in the ossification of the skeleton, and a severe 
mineralization defect of newly synthesized bone matrix. 
Skeletal integrity was so compromised in the D4 line that 
spontaneous fractures occurred. Our inability to generate 
homozygous mice of this line may be related to its severe 
phenotype. 
The progressive, age-dependent nature of the bone loss 
phenotype suggested  a  defect in  bone  remodeling. This 
was substantiated  by histological and kinetic analyses of 
the D4 line indicating increased activities of both osteo- 
blasts and osteoclasts in transgenic bone. The increases in 
mineral apposition rate and osteoid seam width on many 
bone surfaces indicated an increased rate of bone matrix 
deposition by osteoblasts. Osteocyte density and osteopro- 
genitor cell number were also increased, consistent with an 
increased proliferation of osteoprogenitor cells and an in- 
creased rate of osteoblast differentiation. Based on the os- 
teocyte density and mineral apposition rate, we estimate 
that the rate of differentiation of osteoblasts into osteo- 
cytes is increased 5.6-fold in transgenic bone, from N140 
cells/day/mm  2 bone surface in controls, to 790 cells/day/ 
mm  2. Since bone matrix within resorption lacunae did not 
mineralize over the time course of the fluorochrome-label- 
ing experiment, we could not directly assess the rate of its 
production. However, it is likely that this matrix is pro- 
duced at a  rate equal to, if not greater than,  the matrix 
produced on nonresorbed surfaces, because refilled lacu- 
nae usually appeared flush with the level of neighboring 
nonresorbed surfaces. Increased osteoclastic activity was 
apparent from the increased size of cortical resorption la- 
cunae, the pronounced degree of periosteal and endosteal 
resorption,  and  the  thinned  epiphyseal  plates  of older 
mice, and can be inferred from the age-dependent overall 
decrease of bone mass in the presence of increased osteo- 
blastic activity. 
The Role of TGF-fl in Bone Development and Turnover 
Our analysis indicates that overexpression of TGF-132 in- 
creases the activities of osteoblasts and osteoclasts with a 
consequent increase in bone turnover. These results strongly 
suggest that TGF-13, or specifically TGF-132, is a positive 
regulator of bone remodeling in vivo. Unlike the heteroge- 
neous results of previous in vitro and in vivo studies, our 
transgenic  model  shows  that  the  activities  of both  cell 
types increase at steady state when TGF-[32 is deposited 
into  bone  matrix  in  analogous  fashion  to  endogenous 
TGF-~3. The phenotype also  shows  that  the  increase  in 
bone turnover results in a net imbalance between bone re- 
sorption  and  formation,  resulting  in  progressive,  age- 
dependent bone loss, and therefore suggests that TGF-13 
may regulate the coordination of osteoblast and osteoclast 
activities.  Lastly,  the  mineralization  defect  observed  in 
these mice suggests that TGF-132 may negatively regulate 
bone matrix mineralization in vivo. 
Based on the documented responses of osteoblasts and 
osteoclasts to TGF-[3 in vivo and in vitro, the increased 
turnover likely results  from  the  independent  actions  of 
TGF-[~  on  both  cell  types.  It  is  therefore unlikely that 
TGF-13 drives only one step of bone remodeling; instead, 
we speculate that TGF-[3 increases the rate of remodeling 
by potentiating the actions of other molecular mechanisms 
that directly coordinate progression through the remodel- 
ing cycle. Spatial variations in endogenous TGF-13 expres- 
sion levels may contribute to regional or developmental 
differences in remodeling or local rates of mineralization 
within a bone. 
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in  osteoblasts would lead  to  a  defect in  bone turnover. 
Skeletal development and maintenance involve multiple 
levels of spatial and temporal control (Frost, 1985), and 
one might expect an individual growth and differentiation 
factor to affect several of these levels. Emerging evidence, 
however, suggests that the role of individual growth fac- 
tors may be restricted to specific levels of skeletal organi- 
zation. For example, fibroblast growth factors coordinate 
proportional bone growth, while the TGF-[3 related fac- 
tors  BMP-5  and  GDF-5  are  required  to  determine  the 
shape  of several skeletal elements (for review see Erle- 
bacher et  al.,  1995).  Although  TGF-[3 expression levels 
during chondrogenesis could indirectly modify bone shape, 
TGF-[32  overexpression  by  osteoblasts  does  not  affect 
bone growth, skeletal proportions, or bone morphogenesis 
per se (except the clavicle). 
TGF-132 from bone matrix was increased 2.5-fold in D5 
mice. Since TGF-[32 is about 7.5 times less abundant than 
TGF-[31 in normal bone matrix, the progressive bone loss 
of these mice suggests that bone turnover may be sensitive 
over the long term to only minimal changes in total TGF-[3 
content. Additionally, TGF-[32 may induce different cellu- 
lar or more potent responses than TGF-[31. This latter pos- 
sibility is consistent with the higher activity of TGF-[32 in 
inducing cartilage and bone formation (Joyce et al., 1990). 
Such differences in the  actions of TGF-[32 and TGF-[31 
could correlate with differential receptor binding or ex- 
pression in bone cells. 
Regional Differences in the Bone Phenotype 
The histological changes varied depending on the area of 
bone.  Based  on  the  kinetic  analysis  and  the  von Kossa 
staining,  osteoblastic activity was  most perturbed in  the 
epiphysis and diaphysis, yet appeared normal in the meta- 
physis.  These local differences likely result  from differ- 
ences  in  the  local  level  of  expression  of  the  TGF-[32 
transgene.  Indeed, endogenous osteocalcin expression in 
osteoblasts is higher in the epiphysis and diaphysis than in 
the metaphysis of long bones (Bronckers et al., 1985; Ver- 
meulen et al., 1989), and expression from the transgenic 
promoter is accordingly higher in the diaphysis than in the 
metaphysis (Baker et al., 1992). As a result, increased os- 
teoblastic expression of TGF-[32 in transgenic bone was 
more prevalent in the  epiphysis than in the metaphysis. 
The spatial correlation between transgene expression and 
its phenotypic effects strongly suggests that the actions of 
TGF-[32 on osteoblasts are restricted to its site of produc- 
tion within bone. Furthermore, the observation that defec- 
tive mineralization was restricted to the matrix within re- 
sorption lacunae supports the hypothesis that the TGF-[3 
within  bone matrix exerts its  localized effects on osteo- 
blasts after release and activation during osteoclastic re- 
sorption (Pfeilschifter and Mundy, 1987). 
In contrast to osteoblasts, the increase in osteoclastic ac- 
tivity in  transgenic  bone  showed  fewer regional  differ- 
ences. Trabecular bone mass in the metaphysis was dra- 
matically decreased even though transgene expression was 
considerably less there than in the epiphysis and diaphysis. 
This suggests that osteoclastic activity is induced at lower 
local  TGF-[32  concentrations  than  osteoblastic  activity. 
The similar numbers of osteoclasts in normal and trans- 
genic bone further suggests that increased resorption was 
due to increased resorbing activity per osteoclast, a possi- 
bility consistent with the large size of resorption lacunae in 
transgenic bone. 
Relationship of the Transgenic Phenotype to Human 
Bone Diseases 
Cleidocranial Dysplasia. A  notable  feature of D4  mice is 
their defect in clavicle development and general delay in 
ossification. Impaired clavicle development is a hallmark 
of the human autosomal dominant disorder cleidocranial 
dysplasia (Marie and Sainton, 1897; Jones, 1988) as well as 
the  cleidocranial  dysplasia  (Ccd)  mouse  mutation  (Sil- 
lence et al.,  1987).  The Ccd phenotype also includes de- 
layed ossification of a number of bones, and although the 
developmental basis of human cleidocranial dysplasia has 
not been well studied, delayed mineralization of the su- 
tures and pubic bone has been noted. The severe hypopla- 
sia or absence of clavicles in all three cases stands in con- 
trast  with  the  normal  appearance  of most  other bones. 
However, clavicles are remarkable because they are the 
only bones outside the skull which develop via intramem- 
branous ossification and not through cartilage templates 
(Tran and Hall, 1989). Furthermore, clavicle development 
strongly depends upon mechanical stimulation, which may 
in turn depend upon the articulation of the clavicle with 
the sternum (Pai, 1965; Hall, 1986). Thus, clavicle develop- 
ment may be uniquely sensitive to delayed ossification or 
to a TGF-[32-induced inhibition in nearby muscle devel- 
opment (Massagu6 et al., 1986; Olson et al., 1986). The in- 
creased osteoblastic expression of TGF-[32 in  D4  trans- 
genie  mice  may  provide  a  starting  point  to  study  the 
developmental  abnormalities  associated  with  human 
cleidocranial dysplasia and the mouse Ccd phenotype. 
Hyperparathyroidism. The phenotype of the high TGF- 
[32 expressing D4 line showed a remarkable similarity to 
the  skeletal abnormalities  associated with hyperparathy- 
roidism, a disease resulting from increased circulating lev- 
els of parathyroid hormone (PTH) (Malluche and Faugere, 
1990; Kronenberg, 1993). Common features include gener- 
alized  osteopenia,  increased  density  of  osteocytes,  in- 
creased osteoclastic resorption, and high turnover kinetics. 
Increased amounts of unmineralized osteoid apparent in 
our transgenic mice are also commonly seen in hyperpara- 
thyroidism, especially when associated with renal failure 
(renal osteodystrophy), and fibrotic bone surfaces reflect a 
severe hyperparathyroid state termed osteitis fibrosa. 
PTH is thought to maintain systemic calcium homeosta- 
sis in part by regulating osteoclastic bone resorption via an 
indirect mechanism involving osteoblasts (Rodan and Mar- 
tin,  1981;  McSheehy and  Chambers,  1986;  Kronenberg, 
1993).  How increased PTH levels lead to the skeletal de- 
fects in hyperparathyroidism is unknown. The similarity of 
the D4 phenotype with hyperparathyroidism may link the 
local effects of TGF-132 to the systemic actions of PTH. 
The osteoblast-dependent PTH stimulation of osteoclastic 
activity in vitro is  simulated  by TGF-[3 (Hattersley and 
Chambers, 1991), and PTH induces TGF-[3 expression and 
activation by osteoblasts in vitro (Oursler et al., 1991; Yee 
et al., 1993) and TGF-[3 expression in bone in vivo (Pfeil- 
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of osteoblasts to TGF-13 in culture, perhaps by altering the 
TGF-13 receptor expression pattern  of these cells  (Cen- 
trella et al., 1988). Conversely, TGF-13 upregulates the ex- 
pression of PTH receptors in osteoblasts (Schneider et al., 
1992; Seitz et al., 1992), raising the possibility that increased 
TGF-13 expression mimics the  histological phenotype of 
hyperparathyroidism by sensitizing osteoblasts to physio- 
logical levels of PTH. It is highly unlikely that the severe 
D4 phenotype resulted from increased levels of PTH or 
PTH-related peptide, since transgenic mice showed no evi- 
dence of hypercalcemia or hypophosphatemia (Kronen- 
berg, 1993; Strewler and Nissenson, 1993). 
Osteoporosis. Finally, the mild phenotype of the D5 line, 
with its progressive, age-dependent bone loss with little or 
no  alteration  in  the  microscopic  appearance  of  bone, 
closely resembles osteoporosis, a prevalent disease thought 
to result from an imbalance between osteoclastic and os- 
teoblastic activities during bone  remodeling (for review 
see Manolagas and Jilka,  1995).  In addition, bone from 
7-month-old D4 mice were extremely osteoporotic, aside 
from the increased osteocyte density and mineralization 
defect, which  are,  strictly speaking,  not  features  of os- 
teoporotic bone. Furthermore, a hallmark of osteoporosis 
is the increased propensity towards fracturing. Spontane- 
ous fractures were indeed commonly seen in D4 mice, and 
we infer that D5  mice may therefore be more prone  to 
fractures as well. 
Despite the association of osteoporosis with changes in 
the hormonal regulation of bone turnover, such as reduced 
estrogen in the postmenopausal state, the local mediators 
which alter bone remodeling and lead to the imbalance be- 
tween osteoclastic and osteoblastic activities at the histo- 
logical level remain largely unknown. Considering the epi- 
demiological and histological heterogeneity of osteoporosis 
(Meunier et  al.,  1980; Parfitt et  al.,  1980; Whyte et  al., 
1982), and the multiplicity of cytokines and growth factors 
that  affect  osteoblasts  and  osteoclast  function  in  vitro 
(Mundy, 1993),  it is likely that several factors influence 
bone turnover and contribute to the pathogenesis of os- 
teoporosis.  Thus,  transgenic  overexpression  of interleu- 
kin-4 by T cells leads to an osteoporotic phenotype with 
decreased osteoblastic function, suggesting that this factor 
could play a role in low-turnover osteoporosis (Lewis et 
al.,  1993).  Furthermore, mice-deficient mice in interleu- 
kin-6 (IL-6) expression have revealed a requirement for 
this cytokine in the bone  loss that follows ovariectomy, 
which resembles postmenopausal osteoporosis (Poli et al., 
1994). Interestingly, IL-6--deficient mice have an increased 
rate of bone turnover but no discernible bone loss before 
ovariectomy. 
Our  transgenic mice show that increased osteoblastic 
expression of TGF-132, a normal product of osteoblasts in 
vivo, causes both an increase in bone remodeling and an 
imbalance in osteoclastic and osteoblastic activity leading 
to progressive bone loss, a phenotype similar to high-turn- 
over  osteoporosis.  A  potential  link  between postmeno- 
pausal osteoporosis and TGF-13 has previously been made 
with the finding that ovariectomy in rats leads to a 40% 
specific reduction in TGF-13 extractable from bone matrix 
(Finkelman et al.,  1992). However, it is unclear how this 
reduction is causally related to the high turnover state fol- 
lowing ovariectomy (Wronski et al., 1985, 1986), since we 
see a similar reduction in TGF-[31 content of bone matrix 
in our mice overexpressing a high level of TGF-132. The re- 
markable  association of an  osteoporosis-like phenotype 
with only a mild, i.e., 2.5-fold increase in TGF-132 expres- 
sion by osteoblasts that only minimally affects the  total 
TGF-[3 content of bone, suggests that small alterations in 
the expression of TGF-t3 in bone, or in the responsiveness 
of bone cells to TGF-[3, could contribute to the remodeling 
defects underlying osteoporosis and other metabolic bone 
diseases. 
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